Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-PF-06826647-LR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV | EXPERIMENTAL | PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2. |
| Name | Type | Description |
|---|---|---|
| 14C-PF-06826647-LR 600 mg PO | DRUG | 14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep |
| PF-06826647 600 mg PO | DRUG | Unlabeled PF-06826647 600 mg |
| 14C-PF-06826647 100 ug IV | DRUG | 14C-PF-06826647 100 ug IV |
Inclusion Criteria: * Healthy Male participants must be 18 to 55 years of age, inclusive. * Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, including BP and pulse rate measurement, laboratory tests, and 12 lead ECG. * Pa...
14C-PF-06826647-LR is a carbon-14 radiolabeled small molecule developed by Pfizer, Inc. (PFE). It is an investigational drug candidate that has been studied in a Phase 1 clinical trial to assess its mass balance and absolute bioavailability in healthy male participants. The specific therapeutic indication for this drug has not been disclosed.
14C-PF-06826647-LR is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sole sponsor of the clinical program for this investigational small molecule.
14C-PF-06826647-LR is in Phase 1 clinical development. The single Phase 1 trial for this drug has been completed. It is an investigational agent and has not been approved by the FDA for any indication.
14C-PF-06826647-LR has been studied in one completed Phase 1 clinical trial, NCT04591262, titled "A Study To Assess Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants." The trial enrolled 6 healthy male participants in the Netherlands and was an uncontrolled, non-randomized study.